Abstract
Alemtuzumab is active in chronic lymphocytic leukaemia (CLL) patients refractory to alkylators and fludarabine. The aim of this study was to determine the efficacy and safety of subcutaneous alemtuzumab at low dose (10 mg three times per week, for 18 weeks) to 49 patients with pre-treated CLL. The overall response rate was 53%, including 27% of complete responses; it was 42% in patients over 70 years, and 54% in the fludarabine-resistant patients. Forty-five percent of the patients with an unfavourable karyotype responded, including 60% of those with the 17p- aberration. After a median follow-up of 25 months, the median overall time to disease progression was 8 months (responders 12 months, non-responders 4 months). The median overall time to alternative treatment was 9 months (responders 17 months, non-responders 6 months) and median overall survival was 30 months. The treatment was well tolerated: grade IV neutropenia was observed in 17%, and cytomegalovirus (CMV) reactivation in 24% of the patients, with no CMV disease. We observed a total of 30 infections (50% during treatment and 50% during the 12-month follow-up), only one-third of which was severe. This study confirms that low-dose subcutaneous alemtuzumab is effective in poor prognosis CLL, and has a particularly favourable toxicity profile.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561.
Moreno C, Montserrat E . New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008; 22: 211–219.
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.
Faderl S, O'Brien S, Keating MJ . Monoclonal antibody combinations in CLL: evolving strategies. Best Pract Res Clin Haematol 2007; 20: 781–793.
Christian BA, Lin TS . Antibody therapy for chronic lymphocytic leukemia. Semin Hematol 2008; 45: 95–103.
Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukaemia (B-CLL). Blood 2002; 100: 768–773.
Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukaemia. J Clin Oncol 2007; 25: 5616–5623.
Österborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567–1574.
Cortelezzi A, Pasquini MC, Sarina B, Bertani G, Grifoni F, Colombi M et al. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. Haematologica 2005; 90: 410–412.
Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 2337–2342.
Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National cancer institute-sponsored Working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels,, 9th edn. Little, Brown & Co: Boston, MA., 1994, 253–256.
Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278–3281.
Gribben JG, Hallek M . Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009; 144: 818–831.
Österborg A . Practical considerations for alemtuzumab therapy in B-cell chronic lymphocytic leukaemia (B-CLL). Cutting Edge 2006; 11: 3–6.
Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007; 64: 278–291.
Elter T, Molnar I, Kuhlmann J, Hallek M, Wendtner C . Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma 2008; 49: 2256–2262.
Stilgenbauer S, Winkler D, Buhler A, Zenz T, Groner S, Busch R et al. Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H trial of the GCLLSG). Blood 2007; 110 (Part 1): 3120.
Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093–1101.
Lin T, Donohue K, Lucas M, Byrd J, Bengtson E, Peterson B et al. Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB Study 10101. Blood 2007; 110: 755.
Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008; 112: 1288–1295.
Hale G, Rebello P, Brettman L, Fegan C, Kennedy B, Kimby E et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukaemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948–955.
Karlsson C, Lundin J, Kimby E, Kennedy B, Moreton P, Hillmen P et al. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 2009; 144 (1): 78–85.
Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC . Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007; 26: 3644–3653.
Vermeulen LC, Puffer EB, Hallam M, Sollinger HW, Hoke R, Kolesar JM . Stability of alemtuzumab for low-dose induction and test doses. Am J Transplant 2009; 9: 651–652.
Acknowledgements
This study was partially supported by Associazione Italiana Leucemie (AIL), Milan, Italy.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cortelezzi, A., Pasquini, M., Gardellini, A. et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 23, 2027–2033 (2009). https://doi.org/10.1038/leu.2009.148
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.148
Keywords
This article is cited by
-
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Signal Transduction and Targeted Therapy (2023)
-
Targeted Therapy for Chronic Lymphocytic Leukemia: Current Status and Future Directions
Drugs (2015)
-
Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)—a single region experience on consecutive patients
Annals of Hematology (2014)
-
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients
Annals of Hematology (2014)
-
Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis
Bone Marrow Transplantation (2012)